Clinical Trial Search

Primary: Change in Immunization Status — 73; 4 participants — p=<0.001

Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04

Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days

Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted

Primary: Qualitative Summaries of Participant Experience in Focus Group Discussions — 100; 7; 26; 10 number of times reported in FGD

Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT

Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants

Primary: Quality of Life — 3.2; 3.7; 2.8; 3.3 units on a scale — p=0.1340

Primary: Feasibility of the Intervention Scale — 4.78 units on a scale — p=.001

Primary: Number of Moderate to Severe Exacerbation (Defined as Requiring Treatment With Systemic Corticosteroids and/or Antibiotics in the Community or Hospital or…

Primary: Session Attendance — 64; 55 Participants

Primary: Incidence Rate of Ng Plus Ct Detected at Any Site Whilst Individuals Are Screened vs. Not Screened — 0.155; 0.205 Ng or CT cases per study visit

Primary: Linkage to Medication for Opioid Use Disorder (MOUD) — 25; 47; 113; 89 Participants

Primary: Mean Percentage of Pad Weight Gain (PWG) Change — 90.8; 98.5; 99.3; 89.3 Mean percentage of PWG change

Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners

Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71

Primary: Unprotected Sexual Occasions (USOs) — 27.73; 41.50; 8.68; 14.70 USOs per participant — p=0.2964

Primary: Condomless Intercourse Events — 3.14; 3.17; 3.68 Expected events — p=0.141

Primary: IPT Initiation Rate — 0.74; 0.65 events per person-years

Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants

Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…

Primary: Physical Activity - Total Steps Recorded During 24 Weeks — 1345700; 1686395; 1684843 steps

Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05

Primary: Proportion of Patients With a Positive SARS-CoV-2 PCR — 12; 12; 11; 12 Participants

Primary: Syphilis Tests Undertaken — 29; 37 Participants

Primary: Frequency of HIV Testing by Internet-recruited MSM. — 777; 215 Participants

Primary: Any Past Year Physical Intimate Partner Violence Perpetration (Men) and Experience (Women) — 134; 86; 155; 118 Participants — p==0.686

Primary: Cumulative Incidence of ART Initiation 14 Days After Clinical Eligibility in Treatment Eligible HIV-infected Patients — 2585; 3753 participants

Primary: Screening Completion by Outreach Approach and Prior Screening Behavior — 3671; 3960; 1482; 3956 Participants — p=0.05

Primary: Number and Severity of Adverse Events Experienced by Subjects in Low-dose Treatment Groups — 7; 4; 7; 3 Participants